Shinobi Therapeutics is pioneering the development of induced pluripotent stem cell (iPSC) therapies that effectively evade the immune system, thereby enhancing their therapeutic potential. Their innovative immune evasion technology allows iPSC-derived T cell therapies to work in harmony with the patient's immune response, rather than against it. This technology provides a comprehensive shield against various immune challenges, including T-cell responses and antibody-mediated rejection. By focusing on CD8ɑβ iPS-T cell therapies, Shinobi aims to address the significant challenge of solid tumors, which are notoriously difficult to treat. Their approach not only increases the persistence of these therapies but also allows for re-dosing and off-the-shelf availability, making treatments more accessible and cost-effective.

The company's Katana platform is central to its strategy, enabling the creation of a master cell bank of untargeted iPS-T cells that can be rapidly expanded by introducing chimeric antigen receptors (CARs) or T cell receptors (TCRs). This flexibility facilitates faster pipeline development and the potential for better patient outcomes. Shinobi's commitment to advancing cell therapies extends beyond oncology, with aspirations to treat a variety of intractable diseases, including autoimmune disorders. By leveraging their unique technologies and partnerships with leading research institutions, Shinobi Therapeutics is positioned to revolutionize the landscape of cell therapy and improve treatment accessibility for patients worldwide.

United States

Shinobi Therapeutics is developing a new class of hypoimmune CD8ab iPS-T cells for cancer and beyond by using immune evasion to unlock the full potential of iPSCs.

Shinobi Therapeutics

Company Details